To the Editor I read with great interest the article in JAMA Neurology byJoubert and colleagues1 that detailed the clinical features of autoimmune encephalitis (AE) mediated by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antibodies. In this regard, the father of modern-day AE research, Josep Dalmau, and his colleagues2 have published numerous articles that define this category of diseases. Of these disorders, the best characterized, perhaps, is the anti–N-methyl-D-aspartate receptor encephalitis receptor (NMDAR) variant, which is the prototypical AE syndrome. Despite these rapid advances, treatment options for patients with AE remain rather mundane and target-nonspecific. Unfortunately, neurology as a science is driven by discovery rather than therapy—this gap is probably narrowing, if slowly.
Avasarala J. Computer-aided Therapeutics in Treating Autoimmune Encephalitis. JAMA Neurol. 2016;73(1):127-128. doi:10.1001/jamaneurol.2015.3516